<?xml version='1.0' encoding='UTF-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" 
         xmlns:bmdb="http://edrn.nci.nih.gov/rdf/rdfs/bmdb-1.0.0#"
         xmlns:edrn="http://edrn.nci.nih.gov/rdf/schema.rdf#"
         xmlns:edrntype="http://edrn.nci.nih.gov/rdf/types.rdf#" 
         xmlns:dc="http://purl.org/dc/terms/">
 <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:53</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/32"/>
    <bmdb:Description>Annexin 1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including Annexin 1.</bmdb:Description>
    <bmdb:PerformanceComment>The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.
Investigation of Annexin 1 is ongoing.</bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53#31"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53#31">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule>PMID: 18794547</bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
        <bmdb:referencesResource rdf:resource="http://www.compass.fhcrc.org/caretweb/"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53/sensitivity-data-0">
    <bmdb:SensSpecDetail>Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:SpecificAssayType>High throughput platform for quantitative analysis of serum autoantibodies: Serum samples were hybridized with protein microarrays using an individual immunofluorescence protocol. Samples were trypsin-digested and subjected to mass spectrometry analysis on an LTQ-Orbitrap.</bmdb:SpecificAssayType>
    <bmdb:Sensitivity>51</bmdb:Sensitivity>
    <bmdb:Specificity>82</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
</rdf:RDF>
